Promising pharmaceutical agents emerge as sports doping products Nov 19, 2009
SARMs represent a promising class of therapeutics for the treatment of various diseases such as sarcopenia, osteoporosis, benign prostatic hyperplasia (BPH), and cancer cachexia. While none of these agents have yet been approved for therapeutic use, SARMs are gaining popularity in the sports doping community because they are believed to provide the benefits of traditional anabolic/androgenic steroids such as testosterone with fewer unwanted side effects. (EurekAlert!)
House calls: Know Your Stats Sep 18, 2009
Prostate cancer and benign prostatic hyperplasia (BPH) an enlarged prostate which can lead to lower urinary tract symptoms are two concerns that can affect a man s quality of life, and should be discussed with a physician. The new campaign, Know Your Stats, features a comprehensive web and media campaign featuring NFL players past and present. (Kingston Mariner, MA)
10 biggest sleep problems: How to fix them Aug 22, 2009
Men: Get your prostate checked, since inflammation of the prostate, benign prostatic hyperplasia (BPN), and prostate tumors can all cause this symptom. In women, frequent urination can go hand in hand with urinary issues such as , an overactive bladder, urinary tract infections, or cystitis. (Atlanta Journal-Constitution -- Health)
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia Aug 17, 2009
QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate ... About Benign Prostatic Hyperplasia ... Benign prostatic hyperplasia (BPH) is one of the most common... (PR Newswire)
Newly Discovered Gene Fusion May Lead To Improved Prostate Cancer Diagnosis Jul 28, 2009
It is important to distinguish harmful cancer from non-lethal diseases, such as benign prostatic hyperplasia, or enlarged prostate disease that exhibits similar symptoms to prostate cancer, in order to provide effective care, explains Dr. Rubin. Gen-Probe, a biotechnology diagnostics company, has licensed this technology and is currently working with Dr. Rubin, and his collaborator Dr. Arul Chinnaiyan at the University of Michigan, to develop urine tests to screen for gene fusions as a means of... (Science Daily)
Patients With Lower Urinary Tract Symptoms More Likely To Suffer From Metabolic Syndrome Jul 5, 2009
19, 2008) Men with signs of benign prostatic hyperplasia can be helped with a daily dose of erectile dysfunction drug tadalafil (marketed as Cialis) to relieve associated lower urinary tract symptoms. (Apr. (Science Daily)
Painkillers May Prevent Prostate Problems Jun 26, 2009
Such enlargement, called benign prostatic hyperplasia or BPH, is common in men over forty, affecting about 50 percent of men by age 50, and about 75 percent by age 80. The other study was led by Dr. Eric A. Singer, who is chief resident in urology at the University of Rochester Medical Center in New York. (Newsmax)
Painkillers May Be Good for the Prostate Jun 23, 2009
The condition, called benign prostatic hyperplasia, affects many men after age 40. The gland, about the size of a walnut, is below the bladder and surrounds the urine-carrying canal or urethra. (MEDLINEplus)
For Men Over 50, Odds of Eye Discomfort Increases Jun 16, 2009
Among men, increasing age, high blood pressure, benign prostatic hyperplasia (a noncancerous enlargement of the prostate) and the use of antidepressants increase the chances of developing dry eye disease, the study authors explained. "It is an important public health problem, causing increased risk of ocular infections and bothersome symptoms of ocular discomfort, fatigue and visual disturbance that interfere with crucial activities, such as reading, working on a computer and driving a car,"... (MEDLINEplus)
Drug For Urination Difficulties Linked With Complications After Cataract Surgery May 26, 2009
Benign prostatic hyperplasia (BPH; enlarged prostate) affects nearly 3 of 4 men by the age of 70 years, with symptoms of BPH including urination difficulties. A commonly prescribed medication for BPH is tamsulosin, which accounted for more than 1 billion in sales in 2007, according to background information in the article. (Science Daily)
Study Reiterates Eye Risks Linked to Flomax May 21, 2009
Flomax is often prescribed to treat an enlarged prostate, a condition known as benign prostatic hyperplasia, or BPH, which affects almost three of four men 70 and older. Symptoms include difficulty urinating. (MEDLINEplus)
Protox reports 2009 first quarter results May 15, 2009
"Executing the placebo controlled BPH study, TRIUMPH, in a timely fashion is our primary goal and we expect to announce top-line results from this study before the end of this year." 2009 Q1 Highlights - Commenced enrollment of a multi-centre, double-blinded, placebo controlled Phase 2 study of PRX302 (study name: TRIUMPH) in subjects with moderate to severe benign prostatic hyperplasia (BPH) ... Protox's lead program, PRX302 (PORxin), is currently being studied in a Phase 2b placebo controlled... (Canada Newswire)
Urodynamix Receives Financial Contribution From NRC-IRAP to Support Development of NIRS Technology to Improve the Minimally Invasive Treatment (MIT) of Benign Prostatic Hypertrophy (BPH) Apr 28, 2009
The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide. (CCNMatthews Press Releases)
Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial Apr 14, 2009
Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit. (PR Newswire)
Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference Mar 25, 2009
Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at. (PR Newswire)
The Prostate Mar 21, 2009
- By David Plotz - Slate Magazine. Previously published Slate articles made new. (Slate)
High Intensity Focused Ultrasound Physician Training Seminar in Mexico City Mar 17, 2009
Leading HIFU device in Mexico for Minimally Invasive Treatment for Prostate Cancer and Benign Prostatic Hyperplasia draws attention from elite urologists. CHARLOTTE, N.C., March 16 /PRNewswire/ -- Mexico HIFU in conjunction with International HIFU, the Mexican and international entities of USHIFU, a global leader in the development, manufacturing and distribution of high intensity focused ultrasound (HIFU) technologies, will host the very first multiday Sonablate(R) HIFU physician training... (PR Newswire)
AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne Mar 7, 2009
In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based approaches. AndroScience Corporation. (PR Newswire)
Drugs May Help Healthy Men Lower Prostate Cancer Risk Feb 26, 2009
Today, 5-ARIs are used to treat male-pattern baldness and benign prostatic hyperplasia (enlarged prostate) among other non-cancerous conditions. While supporting the guidelines, panel co-chair Dr. Paul F. Schellhammer noted that while 5-ARIs may decrease the risk of getting prostate cancer, it is not known whether these drugs reduce death from the disease. (MEDLINEplus)
New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk Feb 26, 2009
Currently, 5-ARIs are used to treat other non-cancerous conditions, such as male-pattern baldness and benign prostatic hyperplasia. Prostate cancer is the most common non-skin cancer among men and the second-leading cause of cancer death in men. (EurekAlert!)
Panel touts benefits of preventative prostate drug Feb 26, 2009
The drugs, sold under such brand names as Proscar, Propecia and Finpecia, are used to treat other non-cancerous conditions such as male-pattern baldness and benign prostatic hyperplasia. The panel based its recommendations on several studies in particular theProstate Cancer Prevention Trial (PCPT) which compared finasteride against placebo in healthy men over 55, who were receiving regular screening tests for prostate cancer. (Globe and Mail)
AMS posts Q4 profit; COO resigns Feb 18, 2009
Following his resignation, AMS said the general managers of its three businesses Men s Health, Women s Health and Benign Prostatic Hyperplasia (BPH) Therapy now will report directly to Bihl. The company also plans to add a top technology leader to its executive team. (Twin Cities Business Journal, MN)
authors & referees @ NPG Feb 8, 2009
Coverage includes urologic oncology, sexual dysfunction, benign prostatic hyperplasia, urinary incontinence, endourology, trauma and reconstruction, male factor infertility, imaging and radiology, infection and inflammation and pathology. Nature Clinical Practice Endocrinology & Metabolism. (Nature News Service)
Large Prostates Removed with Single-Keyhole Surgery Feb 7, 2009
NEW YORK (Reuters Health) - An enlarged prostate due to benign prostatic hyperplasia, or BPH, can be safely and effectively removed using a type of minimally invasive single-keyhole surgery, researchers report. The procedure, known as single-port transvesical enucleation of the prostate, or STEP, is "indicated in patients with large (greater than 80 to 100 grams) prostate glands that require surgery, in lieu of open surgery," Dr. Mihir M. Desai from the Cleveland Clinic, Ohio told Reuters... (MEDLINEplus)
